Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 10, 2016 - Issue 2
Submit an article Journal homepage
678
Views
6
CrossRef citations to date
0
Altmetric
Drug Profiles

Vedolizumab for the treatment of ulcerative colitis

Andreas StallmachDepartment of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases), University Hospital Jena, Jena, GermanyCorrespondence[email protected]
,
Carsten SchmidtDepartment of Internal Medicine IV (Gastroenterology, Hepatology and Infectious Diseases), University Hospital Jena, Jena, Germany
&
Niels TeichInternistische Gemeinschaftspraxis für Verdauungs- und Stoffwechselkrankheiten, Leipzig, Germany
Pages 165-175 | Received 29 Sep 2015, Accepted 19 Nov 2015, Published online: 15 Dec 2015

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794.
  • Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42; quiz e30.
  • Dignass A, Preiss JC, Aust DE, et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol. 2011;49(9):1276–1341.
  • Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6(10):991–1030.
  • Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroentero. 2014;20(12):3146–3152.
  • Samaan MA, Bagi P, Vande Casteele N, et al.. An update on anti-TNF agents in ulcerative colitis. Gastroenterol Clin North Am. 2014;43(3):479–494.
  • Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148(5):1035–1058 e1033.
  • Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24(2):167–182.
  • Stallmach A, Dennler U, Marschall U, et al.. Patient-relevant endpoints in inflammatory bowel diseases–have changes occurred in Germany over the past twelve years? J Crohns Colitis. 2015;9(5):390–397.
  • Mosli MH, Rivera-Nieves J, Feagan BG. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drugs. 2014;74(3):297–311.
  • Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998;114(5):1066–1090.
  • Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348(1):68–72.
  • Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29(4):397–404.
  • Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2015;14(9):1473–1479.

* This review summarized the safety and side effects of VDZ.

  • Soler D, Chapman T, Yang LL, et al.. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864–875.
  • Zhi K, Li M, Zhang X, et al. alpha4beta7 Integrin (LPAM-1) is upregulated at atherosclerotic lesions and is involved in atherosclerosis progression. Cellular Physiology Biochemistry: International Journal Experimental Cellular Physiology, Biochemistry, Pharmacology. 2014;33(6):1876–1887.
  • Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74(9):1739–1747.
  • Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151(1):97–110.
  • Ala A, Brown D, Khan K, et al. Mucosal addressin cell adhesion molecule (MAdCAM-1) expression is upregulated in the cirrhotic liver and immunolocalises to the peribiliary plexus and lymphoid aggregates. Dig Dis Sci. 2013;58(9):2528–2541.
  • Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18(11):2107–2119.
  • Haanstra KG, Hofman SO, Lopes Estevao DM, et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunology. 2013;190(5):1961–1973.
  • Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. mABS. 2013;5(6):842–850.
  • Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83.
  • Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;111(5):1373–1380.
  • Feagan BG, McDonald JW, Greenberg G. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). Gastroenterology. 2000;118(4 Pt 1):A874.
  • Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470–1479.
  • Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202.
  • Feagan BG, Rutgeerts P, Sands BE, et al.. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.

•• This is a pivotal clinical trial demonstrationg the effectivness and safety of VDZ in induction and maintenance in patients with ulcerative colitis.

  • Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
  • Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618–627 e613.

• This study investigated the efficacy of vedolizumab in Crohn’s disease (CD) patients in whom anti-TNF treatment failed.

• This study investigated real life efficacy of vedolizumab in IBD patients.

  • Jin Y, Lin Y, Lin LJ, et al.. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World Journal of Gastroenterology: WJG. 2015;21(20):6352–6360.
  • Bickston SJ, Behm BW, Tsoulis DJ, et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane DB SYST REV. 2014;8:CD007571.
  • Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterology Journal. 2014;2(5):333–344.
  • Dulai PS, Mosli M, Khanna R, et al.. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015;35(4):412–423.
  • Colombel JF, Sands BE, Hanauer SB, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn’s disease. Am J Gastroenterol. 2013;108(Suppl1):S502.
  • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
  • Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–265 e251–253.
  • Moss AC, Brinks V, Carpenter JF. Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. Aliment Pharmacol Ther. 2013;38(10):1188–1197.
  • Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-alpha antagonists. Ther Clin Risk Manag. 2015;11:63–73.
  • Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13(1):24–30.
  • Takeda G Dossier zur Nutzenbewertung gemäß § 35a SGB V; Vedolizumab (Entyvio®); Modul 4 A. Colitis ulcerosa [Internet]. 2014 [cited 2015 Sep 5]. Available from: https://www.g-ba.de/informationen/nutzenbewertung/125/
  • Gisbert JP, Marin AC, McNicholl AG, et al.. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–623.
  • Schreiber S, Dignass AU, Hartmann H, et al. Vedolizumab bei Colitis ulcerosa und Morbus Crohn: eine Standortbestimmung. Zeitschrift Für Gastroenterologie. 2015;53(6):591–602.
  • Gisbert JP, Chaparro M. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it? Scand J Gastroenterol. 2015;50(4):379–386.
  • Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–1915.
  • Bürger M, Schmidt C, Teich N, et al.. Medical therapy of active ulcerative colitis. Viszerlamedizin. Gastrointest Med Surg. 2015;15(4):236–245.
  • Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–440.
  • van Deen WK, van Oijen MG, Myers KD, et al. A nationwide 2010–2012 analysis of U.S. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20(10):1747–1753.
  • Lee HS, Park SH, Yang SK, et al. Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013: a hospital-based cohort study from Korea. Journal of Crohn’s & Colitis. 2015;9(2):147–155.
  • Tew GW, Hackney JA, Gibbons D, et al. Association between response to etrolizumab and expression of integrin alpha E and granzyme A in colon biopsies of patients with ulcerative colitis. Gastroenterology. 2015 Oct 29. pii: S0016-5085(15)01574-7. doi:10.1053/j.gastro.2015.10.041. [Epub ahead of print]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.